Zsolt P. Ori

, Ori Diagnostic Instruments LLC, USA
Title : Continuous Risk Assessment and Management of Insulin Resistance


There is a need to facilitate efforts to reduce cardiometabolic risks with healthy lifestyle. We recently introduced a Cyber-Physical System (CPS). CPS is a mobile technology integrating sensory data from sensors of the fitness industry into individualized dynamic mathematical models of cardiometabolic processes allowing for analysis and prediction, maximizing control by user, and supported by provider. The main proposition is to perform continuous risk assessment leading to DM2 and complications including cardiovascular disease.
Methods: Closely mimicking HOMA-IR is our metric allowing for the noninvasive observation of insulin resistance changes by estimating Rw-ratio which are defined as Rw=?W/?F where ?W and ?F are weight and fat mass change over 24hrs. We can estimate Rw-ratio with use of Weight, Fat weight, Energy Balance (WFE) model calculation without mandatory calorie counting by serially measuring weight, fat weight, and energy balance. An example of verification of this concept was performed using data from 3 clinical studies of lifestyle modification with 11 clinical study arms which lasted longer than 336 days. CPS is equipped to observe changes of additional state variables (SV’s) of cardiometabolic health including maximum oxygen uptake capacity, heart rate variability, and photoplethysmography estimated blood pressure and total arterial compliance.
Results: The correlation between HOMA-IR and WFE derived Rw-ratio was ?= -0.8481   with P= 0.000969.
Conclusion: Our CPS can provide a truly individualized, non-invasive, quasi real-time tool for continuous observation of insulin resistance and related SV’s in the user’s home environment. CPS can help optimally adjust modifiable risk factors. The trends/trajectories of SV’s can serve as metrics, allowing for planning and executing dynamic changes of lifestyle for targeted optimization and calculate risks of endpoints.


Dr. Ori is a practicing internist and hospitalist with previous training in Bio-Medical Cybernetics (Ilmenau University of Technology, Germany) before entering medical school (Albert Szent-Györgyi Medical School, Szeged, Hungary) and post-doctoral research fellowship in non-invasive cardiology (Northwestern University, Chicago). He holds patented inventions to estimate changes of insulin resistance non-invasively.